Research Paper Volume 12, Issue 22 pp 23165—23186

An eleven metabolic gene signature-based prognostic model for clear cell renal cell carcinoma

Figure 7. Risk score analysis of the 11 metabolic gene signature-based prognostic model in the test group ccRCC patients. (A) Kaplan-Meier survival curve analysis shows the overall survival of high- (n=79) and low-risk (n=79) test group ccRCC patients based on the median risk score calculated using the 11 metabolic gene signature-based prognostic model. (B) Time dependent ROC curve analysis shows the prognostic performance of the 11 metabolic gene signature-based prognostic model in predicting 1-year, 3-year, and 5-year survival times of the high- and low-risk test group ccRCC patients. (C) Heat map shows the expression of the 11 metabolic genes in high- and low-risk test group ccRCC patients. (D) Risk curve analysis of the 11 metabolic genes in high- and low-risk test group ccRCC patients.